Differentiating Primary and Secondary FSGS Using Non-Invasive Urine Biomarkers
Clinical Characteristics and Histopathology in Adults With Focal Segmental Glomerulosclerosis
Population Pharmacokinetic Analysis of Sparsentan in Healthy Volunteers and Patients with Focal Segmental Glomerulosclerosis
Sparsentan Clinical Trials in Glomerular Diseases: Defining Endpoints and a Path Forward in Light of the Parasol Initiative
The Dual Endothelin A and Angiotensin II Type 1 Receptor Antagonist Sparsentan (FILSPARI®) Exhibits a Safe Nonclinical Male Fertility Toxicity Profile
Epidemiology and Burden of Focal Segmental Glomerulosclerosis Among United States Veterans: An Analysis of Veteran’s Affairs Data
Introduction to FSGS
PARASOL: Proteinuria and GFR as Clinical Trial Endpoints in Focal Segmental Glomerulosclerosis
Mechanism of Protective Actions of Sparsentan in the Kidney: Lessons From Studies in Models of Chronic Kidney Disease
Sparsentan: Patient-reported Outcomes in the Phase 3 DUPLEX Study
Sparsentan in Pediatric Patients With Rare Proteinuric Kidney Disease: Preliminary Findings From the EPPIK Study
Health-Related Quality of Life in Adult Patients With Focal Segmental Glomerulosclerosis (FSGS): Sparsentan Versus Irbesartan
Outcomes of the DUPLEX Trial in Patients With Genetic Focal Segmental Glomerulosclerosis (gFSGS)